Protara director granted 31,000 stock options

Protara Therapeutics director Luke M. Beshar received a grant of stock options covering 31,000 shares of common stock.

Rhea-AI Filing Summary

Protara Therapeutics director Luke M. Beshar received a grant of stock options covering 31,000 shares of common stock. These options have an exercise price of $3.94 per share and were awarded as compensation, not purchased in the open market.

The options were granted as an Annual Grant and will vest in full on the first anniversary of the grant date, as long as he continues serving on the board through that date. They will also vest in full upon a Change of Control, if that occurs earlier.

Insider Trade Summary

Grant/Award: 31,000 shares

Grant/Award 1 txn

Insider BESHAR LUKE M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	31,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 31,000 contracts (Direct)

Footnotes (1)

1. F1. 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.

Key Figures

Option grant size: 31,000 options Exercise price: $3.94 per share Shares underlying options: 31,000 shares +3 more

6 metrics

Option grant size 31,000 options Director Annual Grant of stock options

Exercise price $3.94 per share Strike price for granted stock options

Shares underlying options 31,000 shares Common stock underlying the stock options

Options after transaction 31,000 options Total derivative holdings following grant

Vesting schedule 1-year cliff vesting Vests in full on first anniversary of grant

Option expiration June 14, 2036 Expiration date of granted options

Key Terms

Stock Option (Right to Buy), Annual Grant, Change of Control, Common Stock, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Annual Grant financial

"The shares subject to the Annual Grant will vest in full"

Change of Control financial

"and will vest in full upon a Change of Control"

A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Protara Therapeutics (TARA) disclose in this Form 4?

Protara Therapeutics disclosed that director Luke M. Beshar received a grant of stock options for 31,000 shares of common stock. This is a compensation-related award, not an open-market stock purchase or sale.

How many Protara Therapeutics (TARA) options were granted to Luke M. Beshar?

Luke M. Beshar was granted stock options covering 31,000 shares of Protara Therapeutics common stock. These options give him the right to buy that number of shares if he chooses to exercise them in the future.

What is the exercise price of the Protara Therapeutics (TARA) options granted?

The stock options granted to Luke M. Beshar have an exercise price of $3.94 per share. This is the fixed price he would pay per share if he exercises the options during their term.

When do Luke M. Beshar’s Protara Therapeutics (TARA) options vest?

The options will vest in full on the first anniversary of the grant date, subject to his continuous service as a board member. They will also fully vest if a Change of Control happens before that anniversary.

Is the Protara Therapeutics (TARA) Form 4 transaction a market buy or sell?

No, the filing shows a grant of stock options as compensation, coded as an acquisition (A), not a market transaction. Luke M. Beshar did not buy or sell shares in the open market in this disclosure.

What is the expiration date of the Protara Therapeutics (TARA) stock options granted?

The granted stock options are scheduled to expire on June 14, 2036. After that expiration date, any unexercised options will no longer be usable to purchase Protara Therapeutics common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/16/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BESHAR LUKE M

(Last) (First) (Middle)

C/O PROTARA THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, 3RD FLOOR

(Street)

NEW YORK NEW YORK 10010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Protara Therapeutics, Inc. [ TARA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.94	06/15/2026		A		31,000		06/15/2027(1)	06/14/2036	Common Stock	31,000	$0	31,000	D

Explanation of Responses:

1. 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.

Remarks:

	/s/ Mary Grendell, Attorney-in-fact	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)